Ultragenyx Pharmaceutical (RARE) said the U.S. FDA granted accelerated approval for GENGLYCOS (DTX401) for glycogen storage disease type Ia in patients aged 8+ (adult and pediatric). The expedited approval is a material regulatory milestone that can expand near-term addressable demand and improve the stock’s outlook on expected future sales and approvals.
Ultragenyx Pharmaceutical (RARE) said the U.S. FDA granted accelerated approval for GENGLYCOS (DTX401) for glycogen storage disease type Ia in patients aged 8+ (adult and pediatric). The expedited approval is a material regulatory milestone that can expand near-term addressable demand and improve the stock’s outlook on expected future sales and approvals.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
